Rajat brings investment experience from roles at Wren Capital, ACF Investors, and Cambridge Angels. He also serves as a non-executive director at Momentum Bioscience.
The funding round was led by The Yield Lab, STIHL Ventures, and ACF Investors to drive global product growth.
"The Spotta platform built by Robert, Neil and the team delivers a real solution which can completely turn the insect pest control industry on its head. With their smart 24/7 monitoring enabling customers to precision target treatment for the first time. It’s a solution that protects people and crops but also hugely reduces the cost and environmental impact of treatment."
MP Healthcare led the pre-Series A financing to help fund the expansion of the company drug discovery pipeline in oncology and neurology.
"At PharmEnable, we believe that everyone deserves safe and effective treatments, and we are committed to applying the principles chemical novelty, diversity and 3-dimensionality to design powerful new small molecule drugs."
The biomedical startup has closed a £2.3m Series A round backed by Mercia Asset Management, ACF Investors, Wren Capital and Wealth Club.
"Adapttech brought its first product to market during 2021, successfully securing a number of sales. We are delighted to be supporting the team with a follow-on investment to continue to scale the business and build out the product portfolio."
Catapult Ventures led the seed round alongside Neo Kuma Ventures, Wren Capital, and o2H ventures to support the Cambridge Cognition spinout.
"By establishing Monument Therapeutics, we have created an exciting new venture to develop stratified medicine in CNS drug development that could help many patients with unmet clinical needs. It leverages Cambridge Cognition’s intellectual property and provides the potential for considerable royalty payments in the future, while the Company continues to focus on the development and commercialisation of its cutting-edge digital health technologies."
The seed round was supported by a syndicate of investors including the Development Bank of Wales and the UKI2S Innovate Accelerator to fund platform development and laboratory expansion.
"Our investors recognise the potential of our AI-powered antibody drug discovery platform to provide a breakthrough in the industry. With our technology, it will be possible to develop drugs for difficult targets and ultimately reduce drug discovery timescales from years to weeks. In addition to platform development, the funding will enable us to invest in facilities and recruitment; we are grateful to our investors and Innovate UK for their continued support."
Cambridge Angels and REMUS led the seed round to support international expansion and product development.
"For decades, pest management has been held back by laborious, error-prone manual monitoring. With our technology it is finally possible to change this and help industries around the world to make a step change from reactive to proactive management of pests. This will save billions and massively reduce the amount of pesticide used globally. We’re delighted to have strong support from a wide group of investors who share our vision. This funding will allow us to scale up our commercial operations and continue to address the £320bn global problem of insect pests."
The oversubscribed round was led by Cambridge Enterprise and will fund the company's transition into drug development.
"We are pleased to welcome on board our new investors and appreciate their confidence in our business. Our aim is to replicate the specificity of biologics in the powerful and scalable form of a small molecule, to treat devastating diseases where there are currently no treatment options. We have proven the strength of our platform in tapping unexplored parts of the chemical universe to find novel and specific hits for currently undruggable targets, and are excited to now be able to invest in our own pipeline of drug discovery programmes, as well as to develop further strategic partnerships."
.png)
